All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells

ABSTRACT Acute myeloid leukemia (AML) is an aggressive, often fatal hematopoietic malignancy. All-trans retinoic acid (atRA), one of the first molecularly targeted drugs in oncology, has greatly improved the outcome of a subtype of AML, acute promyelocytic leukemia (APL). In contrast, atRA has so far provided little therapeutic benefit in the much larger group of patients with non-APL AML. Attempts to identify genetically or molecularly defined subgroups of patients that may respond to atRA have not yielded consistent results. Since AML is a stem cell-driven disease, understanding the effectiveness of atRA may require an appreciation of its impact on AML stem cells. Recent studies reported that atRA decreased stemness of AML with an FLT3-ITD mutation, yet increased it in AML1-ETO driven or EVI1-overexpressing AML. This review summarizes the role of atRA in normal hematopoiesis and in AML, focusing on its impact on AML stem cells.

[1]  Richard J. Jones,et al.  Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids , 2020, Leukemia.

[2]  I. Asangani,et al.  Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression , 2020, Cell.

[3]  Yanhua Yue,et al.  Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  D. Vetrie,et al.  The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML , 2020, Nature Reviews Cancer.

[5]  A. Fatica,et al.  Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. , 2019, Blood advances.

[6]  K. Döhner,et al.  Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Zuber,et al.  All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia , 2019, Cell Death & Disease.

[8]  G. Martinelli,et al.  The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML , 2019, Leukemia.

[9]  F. Lo Coco,et al.  The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia. , 2019, Blood.

[10]  A. Ganser,et al.  Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia. , 2019, Blood.

[11]  E. Estey,et al.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.

[12]  L. Bullinger,et al.  New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise , 2019, International journal of molecular sciences.

[13]  S. Kogan,et al.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. , 2019, Blood.

[14]  P. Frenette,et al.  Haematopoietic stem cell activity and interactions with the niche , 2019, Nature Reviews Molecular Cell Biology.

[15]  J. Schwaller,et al.  The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models , 2019, HemaSphere.

[16]  M. McKeown,et al.  Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia , 2018, Haematologica.

[17]  C. S. Grace,et al.  Protagonist or antagonist? The complex roles of retinoids in the regulation of hematopoietic stem cells and their specification from pluripotent stem cells. , 2018, Experimental hematology.

[18]  M. Lübbert,et al.  Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). , 2018, The Cochrane database of systematic reviews.

[19]  A. Pandith,et al.  Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility , 2018, Clinical genetics.

[20]  E. Letouzé,et al.  Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia , 2018, Nature Communications.

[21]  E. Campo,et al.  A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression , 2018, Nature Communications.

[22]  S. Haas,et al.  Causes and Consequences of Hematopoietic Stem Cell Heterogeneity. , 2018, Cell stem cell.

[23]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[24]  M. Piechaczyk,et al.  Targeting the SUMO pathway primes all-trans-retinoic acid-induced differentiation of non promyelocytic Acute Myeloid Leukemias , 2018, bioRxiv.

[25]  B. Göttgens,et al.  From haematopoietic stem cells to complex differentiation landscapes , 2018, Nature.

[26]  V. Beneš,et al.  The molecular signature of AML with increased ALDH activity suggests a stem cell origin , 2018, Leukemia & lymphoma.

[27]  M. Gasparetto,et al.  ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. , 2017, Chemico-biological interactions.

[28]  Richard J. Jones,et al.  Retinoic acid, CYP26, and drug resistance in the stem cell niche. , 2017, Experimental hematology.

[29]  A. Berghold,et al.  Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. , 2017, Blood.

[30]  V. Beneš,et al.  Vitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy , 2017, Cell.

[31]  M. Schimek,et al.  Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. , 2017, Blood.

[32]  P. Trainor,et al.  New insights and changing paradigms in the regulation of vitamin A metabolism in development , 2017, Wiley interdisciplinary reviews. Developmental biology.

[33]  R. Majeti,et al.  Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.

[34]  H. Hackl,et al.  Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[35]  R. Muñoz-Chápuli,et al.  Role of Vitamin A/Retinoic Acid in Regulation of Embryonic and Adult Hematopoiesis , 2017, Nutrients.

[36]  J. Moreb,et al.  Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells , 2017, Cancer Chemotherapy and Pharmacology.

[37]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[38]  Tae Kon Kim,et al.  Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities , 2016, World journal of stem cells.

[39]  K. Döhner,et al.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.

[40]  E. Pronier,et al.  Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia , 2016, Nature Communications.

[41]  J. George,et al.  Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells , 2016, Nature Communications.

[42]  M. Kyba,et al.  MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. , 2016, Cancer cell.

[43]  Geoffrey Brown,et al.  Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review , 2016, Expert opinion on therapeutic patents.

[44]  F. Ramos,et al.  Acute myeloid leukemia in the older adults , 2016, Leukemia research reports.

[45]  Richard J. Jones,et al.  All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. , 2016, Blood.

[46]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[47]  C. Junot,et al.  Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia , 2016, The Journal of experimental medicine.

[48]  G. Ossenkoppele,et al.  Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. , 2016, Blood.

[49]  Xiangyuan Wang,et al.  Prolonged Oral Administration of a Pan-Retinoic Acid Receptor Antagonist Inhibits Spermatogenesis in Mice With a Rapid Recovery and Changes in the Expression of Influx and Efflux Transporters. , 2016, Endocrinology.

[50]  D. Grimwade,et al.  Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.

[51]  S. Miyano,et al.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. , 2015, Blood.

[52]  K. Kreuzer,et al.  Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) , 2015 .

[53]  F. Ravandi,et al.  Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions , 2015, Drugs & Aging.

[54]  Daniel E. Johnson,et al.  An ATRActive future for differentiation therapy in AML. , 2015, Blood reviews.

[55]  Jace W. Jones,et al.  All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment , 2015, PloS one.

[56]  H. Dombret,et al.  Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. , 2015, Blood.

[57]  B. Falini,et al.  Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. , 2015, Blood.

[58]  F. Lo‐Coco,et al.  Targeting of leukemia-initiating cells in acute promyelocytic leukemia. , 2015, Stem Cell Investigation.

[59]  J. Welch,et al.  Absence of natural intracellular retinoids in mouse bone marrow cells and implications for PML-RARA transformation , 2015, Blood Cancer Journal.

[60]  J. Gołąb,et al.  Cancer stem cells in haematological malignancies , 2015, Contemporary oncology.

[61]  A. Jauch,et al.  The rarity of ALDH + cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients , 2015, International journal of cancer.

[62]  G. Duester,et al.  Mechanisms of retinoic acid signalling and its roles in organ and limb development , 2015, Nature Reviews Molecular Cell Biology.

[63]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[64]  J. Ablain,et al.  Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia , 2014, International journal of cancer.

[65]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[66]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[67]  H. Hackl,et al.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid , 2014, Cell cycle.

[68]  R. Majeti,et al.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis , 2014, Leukemia.

[69]  T. Somervaille,et al.  The variety of leukemic stem cells in myeloid malignancy , 2014, Oncogene.

[70]  Lincoln D. Stein,et al.  Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.

[71]  I. Weissman,et al.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.

[72]  S. Minucci,et al.  Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure , 2014, Nature Medicine.

[73]  J. Frangos,et al.  Rescue of a primary myelofibrosis model by retinoid-antagonist therapy , 2013, Proceedings of the National Academy of Sciences.

[74]  Richard J. Jones,et al.  Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling , 2013, Proceedings of the National Academy of Sciences.

[75]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[76]  G. McArthur,et al.  ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells , 2013, Leukemia.

[77]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[78]  H. de Thé,et al.  Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies , 2013, The Journal of experimental medicine.

[79]  S. Armstrong,et al.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML , 2013, Leukemia.

[80]  R. Wieser,et al.  EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. , 2012, Anticancer research.

[81]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[82]  S. Armstrong,et al.  EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. , 2012, Blood.

[83]  T. Kadowaki,et al.  Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity , 2011, The Journal of experimental medicine.

[84]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[85]  M. Kurokawa,et al.  Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. , 2011, Blood.

[86]  K. Döhner,et al.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  J. Chute,et al.  TISSUE-SPECIFIC STEM CELLS Inhibition of Aldehyde Dehydrogenase Expands Hematopoietic Stem Cells with Radioprotective Capacity , 2010 .

[88]  R. Hills,et al.  The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. , 2010, Blood.

[89]  M. Lerch,et al.  Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. , 2009, Gastroenterology.

[90]  R. Wieser,et al.  Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response , 2009, The FEBS journal.

[91]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[92]  M. D. Leibowitz,et al.  Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture. , 2009, Molecular endocrinology.

[93]  Cécile Rochette-Egly,et al.  Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs) , 2009, Nuclear receptor signaling.

[94]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[95]  P. Pandolfi,et al.  Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation , 2008, Nature Medicine.

[96]  E. Zwarthoff,et al.  MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression. , 2008, Carcinogenesis.

[97]  S. Ogawa,et al.  Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. , 2008, Cell stem cell.

[98]  B. Löwenberg,et al.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. , 2008, Blood.

[99]  R. Wieser,et al.  Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration , 2008, Genes, chromosomes & cancer.

[100]  A. Schambach,et al.  MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. , 2007, Blood.

[101]  R. Wieser.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. , 2007, Gene.

[102]  I. Bozzoni,et al.  Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. , 2007, Blood.

[103]  C. Kenific,et al.  Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. , 2006, Cancer research.

[104]  J. Whitesides,et al.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[105]  P. Chambon,et al.  RARγ is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation , 2006, The Journal of experimental medicine.

[106]  R. Wieser,et al.  Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends. , 2005, Gene.

[107]  G. Ravera,et al.  Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha. , 2005, Cancer letters.

[108]  S. Fröhling,et al.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia , 2004, Leukemia.

[109]  P. Venugopal,et al.  Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. , 2004, Leukemia research.

[110]  S. Collins.  The role of retinoids and retinoic acid receptors in normal hematopoiesis , 2002, Leukemia.

[111]  E. L. Jones,et al.  Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells , 2001, British Journal of Cancer.

[112]  I. Bernstein,et al.  All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. , 2000, Blood.

[113]  I. Bernstein,et al.  All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. , 1999, Blood.

[114]  L. Wagner,et al.  Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia , 1997, Leukemia.

[115]  M. Minden,et al.  Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. , 1994, Leukemia.

[116]  M. Lishner,et al.  Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. , 1989, Leukemia.

[117]  H. Koeffler,et al.  Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. , 1982, Experimental cell research.

[118]  N. Kedishvili.  Retinoic Acid Synthesis and Degradation. , 2016, Sub-cellular biochemistry.

[119]  K. Döhner,et al.  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.